62627-08-1

Upstream product

• 79364-37-7 (+/-)-1-(2-phenylethyl)-3-butenyl acetate 
• 58547-18-5 6-phenyl-4-hydroxyhexan-2-one 
• 104-53-0 3-phenyl-propionaldehyde 

Downstream Products

• 75677-81-5 ethyl 5-acetoxy-3-hydroxy-3-methyl-7-phenylheptanoate 
• 69172-23-2 5H-r,cis-3-hydroxy-trans-3-methyl-7-phenylheptan-5-olide 
• 69172-23-2 5H-r,trans-3-hydroxy-cis-3-methyl-7-phenylheptan-5-olide 

Relevant academic research and scientific papers

Synthesis of macrosphelides H and G

A compound with furyl and vinyl groups was designed as an intermediate for synthesis of macrosphelide H. The furyl group was oxidatively transformed into the key C(5)-O(10) part by a two-step conversion of (1) NBS, H2O; (2) NaClO2 without affecting the free hydroxyl group at C(3), thus furnishing the seco acid, while the Wacker oxidation at the final step was used to convert the vinyl group into acetyl group to afford macrosphelide H. This strategy was applied successfully to synthesis of macrosphelide G as well.

Mevalonolactone derivatives

This invention concerns novel mevalonolactone derivatives having the formula STR1 wherein A represents a direct linkage, methylene, ethylene, trimethylene or vinylene group; R1 represents hydrogen atom, or an aliphatic acyl group, benzoyl group, or a benzoyl group substituted with hydroxy, lower alkoxy, aliphatic acyloxy or halogen; R2 represents hydrogen atom, a halogen atom or methyl group; and R3, R4 and R5 are same or different and each represents hydrogen atom, a halogen atom, a lower alkyl group with or without halogen as the substituent, phenyl group, or a phenyl group substituted with halogen, lower alkoxy, aliphatic acyloxy or lower alkyl with or without halogen, or a group represented by the formula R6 O-- (in the formula, R6 means hydrogen atom, an aliphatic acyl group, benzoyl group, phenyl group, a phenylalkyl group, cinnamyl group, or a group of benzoyl, phenyl, phenylalkyl or cinnamyl in all of which the aromatic ring is substituted with hydroxy, halogen, lower alkoxy, aliphatic acyloxy or lower alkyl with or without halogen as the substituent, or a lower alkyl group with or without halogen as the substituent). The compounds are useful for the treatment of hyperlipidemia. They may be prepared by halo-lactonizing the corresponding γ,δ-unsaturated carboxylic acid derivatives and optionally dehalogenating the resulting product, or lactonizing the corresponding δ-hydroxy-carboxylic acid derivatives.